Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
Shanghai Stock ExchangeTotal Valuation
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. carries a market capitalization of 36.36B, placing it among publicly traded companies globally. Its enterprise value stands at 53.51B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 36.36B |
| Enterprise Value | 53.51B |
Share Statistics
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. currently has 1.26B shares outstanding.
| Shares Outstanding | 1.26B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 44.26, and the price-to-book ratio stands at 7.07.
| PE Ratio | N/A |
| PS Ratio | 44.26 |
| PB Ratio | 7.07 |
| P/TBV Ratio | 5.17 |
| P/FCF Ratio | 91.18 |
| P/OCF Ratio | N/A |
Enterprise Valuation
| EV / Sales | 41.58 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 84.00 |
Financial Position
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. maintains a current ratio of 4.21, meaning it holds 4.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.96, indicating elevated leverage, while an interest coverage ratio of -19.31 demonstrates limited ability to service its debt obligations.
| Current Ratio | 4.21 |
| Quick Ratio | 2.48 |
| Debt / Equity | 2.96 |
| Debt / EBITDA | -1.27 |
| Interest Coverage | -19.31 |
Financial Efficiency
| Return on Equity (ROE) | -4.35 |
| Return on Assets (ROA) | -2.54 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.68 |
Taxes
| Income Tax | -60.37M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.'s stock has declined approximately -51.9144% over the past 52 weeks. The 50-day moving average sits at 34.60, while the 200-day moving average is 43.53.
| Beta (5Y) | N/A |
| 52-Week Price Change | -51.9144% |
| 50-Day Moving Average | 34.60 |
| 200-Day Moving Average | 43.53 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. generated 1.29B in revenue and converted that into -359.09M in net income, yielding earnings per share of -0.26. EBITDA reached -279.27M, while operating income came in at -279.27M.
| Revenue | 1.29B |
| Gross Profit | 702.37M |
| Operating Income | -279.27M |
| Pretax Income | -436.68M |
| Net Income | -359.09M |
| EBITDA | -279.27M |
| EBIT | -279.27M |
| Earnings Per Share (EPS) | -0.26 |
Balance Sheet
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. holds 3.96B in cash and equivalents against 355.03M in total debt, resulting in a net debt position of -2.15B. Total book value stands at 8.06B, with working capital of 5.13B providing operational flexibility.
| Cash & Cash Equivalents | 3.96B |
| Total Debt | 355.03M |
| Net Debt | -2.15B |
| Equity (Book Value) | 8.06B |
| Book Value Per Share | 5.62 |
| Working Capital | 5.13B |
Cash Flow
After subtracting -624.64M in capital expenditures, free cash flow totaled -624.64M - equivalent to -0.44 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -624.64M |
| Free Cash Flow | -624.64M |
| FCF Per Share | -0.44 |
Margins
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. operates with a gross margin of 54.58, reflecting its pricing power and cost economics. The operating margin of -21.70 and net profit margin of -27.90 provide insight into operational efficiency.
| Gross Margin | 54.58 |
| Operating Margin | -21.70 |
| Pretax Margin | -33.93 |
| Profit Margin | -27.90 |
| EBITDA Margin | -21.70 |
Dividends & Yields
The company's payout ratio of -0.43 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.00 |
| Dividend Yield | N/A |
| Payout Ratio | -0.43 |
| Shareholder Yield | 0.06 |
| FCF Yield | 1.10 |
Stock Splits
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.'s most recent stock split took place on June 5, 2023 with a 5:7 split ratio.
| Last Split Date | 6/5/2023 |
| Split Ratio | 5:7 |
Scores
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. posts an Altman Z-Score of 20.53, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 20.53 |